News headlines about Bioverativ (NASDAQ:BIVV) have been trending somewhat positive on Sunday, Accern Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Bioverativ earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 45.7111326202686 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the media headlines that may have effected Accern’s analysis:
- Study Shows Weekly Prophylactic Treatment with ELOCTATE® Resulted in Bleed Protection and Target Joint … – Business Wire (press release) (businesswire.com)
- Study Shows Weekly Prophylactic Treatment with ELOCTATE … – Business Wire (press release) (businesswire.com)
- Study Shows Weekly Prophylactic Treatment with ELOCTATE® Resulted in Bleed Protection and Target Joint Resolution in People with Hemophilia A (finance.yahoo.com)
- ALPROLIX® Demonstrates Higher Tissue Distribution and Retention in Joints Compared to Other Factor IX Molecules in a Preclinical Imaging Study (finance.yahoo.com)
- ETFs with exposure to Bioverativ, Inc. : December 4, 2017 (finance.yahoo.com)
A number of research analysts recently issued reports on BIVV shares. Zacks Investment Research lowered Bioverativ from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 1st. Deutsche Bank set a $53.00 target price on Bioverativ and gave the stock a “hold” rating in a report on Monday, November 20th. Argus raised Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 target price on the stock in a report on Wednesday, September 20th. Evercore ISI started coverage on Bioverativ in a report on Wednesday, August 16th. They set an “in-line” rating and a $58.00 target price on the stock. Finally, Royal Bank Of Canada started coverage on Bioverativ in a report on Thursday, September 14th. They set a “sector perform” rating and a $59.00 target price on the stock. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Bioverativ has an average rating of “Hold” and an average price target of $60.93.
Bioverativ (NASDAQ:BIVV) last released its quarterly earnings results on Thursday, October 26th. The biotechnology company reported $0.80 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.55 by $0.25. Bioverativ had a return on equity of 69.03% and a net margin of 40.44%. The business had revenue of $291.60 million during the quarter, compared to analyst estimates of $285.45 million. The company’s revenue for the quarter was up 27.2% compared to the same quarter last year. research analysts expect that Bioverativ will post 2.45 earnings per share for the current fiscal year.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with MarketBeat.com's FREE daily email newsletter.